drugset
drugset / Trial / NCT01283997

Prevention of Treatment Induced Neuropathy in Multiple Myeloma

NCT01283997 ↗

Phase 2 Completed 79 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
RandomizedSingle-groupTriple-blindTreatment

Summary

The goal of this clinical research study is to see if Minocin® (minocycline) can help to control nerve damage that causes numbness and tingling in the hands and feet (neuropathy) in patients receiving thalidomide and/or bortezomib.

Timeline

Start
2011-01-25
Primary completion
2022-08-22
Completion
2022-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Minocycline Small molecule 100 mg Oral

Indications

plasma cell myeloma